Vertex CSO David Altshuler discusses non-opioid pain pills, AI, and the potential for a groundbreaking drug
David Altshuler, Chief Scientific Officer of Vertex Pharmaceuticals, implemented a unique R&D strategy that focused on targeting specific diseases such as sickle cell and type 1 diabetes and utilizing various tools and platforms, including CRISPR-Cas9 and cell therapy, to develop treatments. The company's CRISPR therapy for sickle cell is awaiting approval and could potentially be the first of its kind on the market.